Metformin’s Potential Role in PCO

Common diabetes therapy reaches intraocular lens tissue and may help limit posterior capsule opacification, says newly published data

By
Conexiant News Staff
March 5, 2026
3 min

Conexiant

Overview

Metformin, a commonly prescribed antidiabetic drug, has shown promise in reducing the incidence of posterior capsule opacification (PCO) following cataract surgery. A study demonstrated that metformin accumulates in the human lens capsule and suppresses lens epithelial cell proliferation, suggesting a potential adjunctive role in PCO management.

Background

Posterior capsule opacification (PCO) is a frequent complication occurring in 20%–30% of patients within five years post-cataract surgery. Current treatment options, such as Nd:YAG laser capsulotomy, carry risks and do not prevent PCO. Understanding the role of medications like metformin in PCO pathogenesis could lead to improved management strategies.

Data Highlights

Parameter	Findings
Patient Population	20 patients with type 2 diabetes mellitus
Metformin Detection	Detected in all anterior lens capsule specimens
Correlation	Significant correlation between capsule and serum concentrations
In Vitro Proliferation	Metformin reduced LEC proliferation in cultured explants

Key Findings

Metformin is detectable in the human lens capsule after systemic administration.
Capsule concentrations of metformin do not significantly differ between low-dose and high-dose groups.
Serum metformin levels showed variability among patients, reflecting pharmacokinetic differences.
In vitro studies indicated that metformin significantly attenuates LEC proliferation.
The findings suggest that metformin may modify PCO risk, potentially offering a protective effect.

Clinical Implications

The results indicate that metformin could serve as a pharmacological adjunct to current mechanical strategies for preventing PCO. Clinicians should consider the implications of antidiabetic medications on PCO risk when managing patients with diabetes undergoing cataract surgery.

Conclusion

This study provides the first direct evidence of metformin's accumulation in the lens capsule and its potential to suppress LEC proliferation, warranting further investigation in larger studies.